TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Detection of cancer of the cervix or precancerous lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ADC value of MRI diffusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medically attended RSV acute lower respiratory tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: RSV hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: RSV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in percent mammographic breast density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: second progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Height Standard Deviation Score (SDS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in knowledge regarding diet and exercise
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in behavior regarding diet and exercise
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Level of anti glial fibrillary acid protein antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change From Baseline in Maximum Keratometry (Kmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants helping with first injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Index
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Highest score obtained at the OAG scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sustained Virological Response 4 (SVR4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients evaluable for survival
Endpoint domain: Mortality/survival
Primary endpoint: Adverse events according to CTCAE version 3 criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Dose of MFE23 scFv-expressing T lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Meeting Partial Mayo Score Response Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (peak time, Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Achieving CD34+ HSC Mobilization Target
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in CBF during RI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reports of shortness of breath, chest pain, fatigue, or hypoxia
Endpoint domain: Adverse events/effects
Primary endpoint: Percentages of Subjects With Human Serum Bactericidal Assay (hSBA) Titers ≥ 1:8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Patient-Reported Outcome Measures (PROMS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Feasibility of device implant procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cortical Thickness of Radius
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients who met the intubation criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of patients who are actually intubated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tissue analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Problem Areas in Diabetic (PAID) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Insulin-mediated Glucose Disposal Rate at Levothyroxine Treatment Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin-mediated Glucose Disposal Rate at Liothyronine Treatment Phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Melbourne Assessment Scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of Hemagglutination Inhibition Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Seroconversion Post-vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improved patient-centered outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Post Nasal Drainage Symptom Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in sSL from baseline to end of study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of flu symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of unexpected adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of expected adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of TD on pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best-Worst Scaling scores for patient preferences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Patient Self Assessment of Clinically Useful Depression Outcome Scale (CUDOS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Speech recognition in quiet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of video intervention use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Negative Polymerase Chain Reaction assay at day 0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Polymerase Chain Reaction assay at day 60
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Lesion counts in total face
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Acute insulin response (AIR) to glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time Until Patient is Ready for Discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: retention in treatment
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: HIV-1 RNA Change from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax ratio of PF-06372865 alone vs coadministration with itraconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC ratio of PF-06372865 alone vs coadministration with itraconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1/2 of PF-06372865 alone vs coadministration with itraconazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to normalization of bicarbonate and pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of nutrition and psychosocial aspects
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Acceptability [Participant Satisfaction]
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adherence [Participant-reported Adherence to Home Exercise Using a Likert Scale]
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Measurement of cardiac output (Q)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Measurement of oxygen consumption (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with 50% Reduction in Depression Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absenteeism rate due to gastrointestinal or respiratory illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Clinically significant pharmacokinetic drug interaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of patients without VAD-related adverse event requiring medical intervention
Endpoint domain: Adverse events/effects
Primary endpoint: % of patients whose intended or additional I.V treatments could be completed with the VAD without VAD complications, dysfunctions or limitations
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Lower Facial Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paced Auditory Serial Addition Test (PASAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Conners Continuous Performance Test 2 (CPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Rey auditory verbal learning test (RAVLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: First Epidural top-up time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Armodafinil DAT Occupancy in Caudate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Armodafinil Extracellular Dopamine in Caudate at 2.5 Hours (With Outlier)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Armodafinil Extracellular Dopamine in Caudate at 2.5 Hours (Without Outlier)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathogens detected in nasal mucus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Mean Systolic Blood Pressure at Final Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Mean Diastolic Blood Pressure at Final Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Geometric mean concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in confidence in CTI principles
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Pmsf-arm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Response of Venetoclax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum drug concentration of nifurtimox in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Closure of oronasal fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Volume of newly formed bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average density of newly formed bone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of thoracic paravertebral block analgesia duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incretin sensitivity of pancreatic beta cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: % of patients with a distinctive feature at the sensory profile questionnaire
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of patients with a failure at the muscle tone test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of patients with a failure at the gross motor test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Needle insertion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Needle alignment time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to target
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with successful urine collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of bacterial contamination among samples
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency and severity of vascular side effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Frequency and severity of metabolic side effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency and severity of hormonal side effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement in psychometric hepatic encephalopathy score (PHES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Minimal Hepatic Encephalopathy (MHE) reversal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sleep apnea symptoms
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: No flow fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak SOWS Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment efficacy (CR+PR+SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal, hematologic, and clinical toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Vascular access function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of de novo reflux esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Safety and tolerability of T3011
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Global Impression
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in time spent in informal care at month 3
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline in time spent in informal care at month 12
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Pulmonary Complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants With CRISS Score >= 60%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30-day Major Adverse Cardiac Event (MACE) Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Pain reduction during dressing changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time From Randomization to Confirmed Abnormal Glucose Tolerance Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the receiver operating characteristic curve (AUC) for Salt loading test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for captopril challenge test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for fludrocortisone suppression test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Experienced Venous Thromboembolism Event (VTE)
Endpoint domain: Mortality/survival
Primary endpoint: Change in amplitude of N400 ERP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Bone mineral density loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Radiographic hernia recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Brief Fear of Negative Evaluation-II
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: spleen and liver size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: disease related constitutional symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transfusion dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: anemia response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with prohibitive dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Hematoma occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline FEV1 % predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Main Thoracic Cobb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scoliosis Research Society-30 Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total Leak Volume of Non Invasive Ventilation Mask
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive Reaction Time Test response speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement in EDSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cutaneous Augmentation Grading Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fibromyalgia Impact Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean neck pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pattern of Homeostasis Disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cerebrospinal fluid levels of Alzheimer's disease biomarkers (CSF beta-amyloid 42)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with injury risk alleles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of functional autonomy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of patients achieving HbA1c level < 8% and < 7.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of identifying sentinel lymph node
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Headache Pain Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of provider interventions done per patient
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Total number of malfunctions present throughout the trial
Endpoint domain: Adverse events/effects
Primary endpoint: Pulmonary regurgitant volume and fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of postoperative cough
Endpoint domain: Adverse events/effects
Primary endpoint: Duruoz Hand Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major device complication rates at 12 months
Endpoint domain: Adverse events/effects
Primary endpoint: Bladder wall thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart beating quickly and strongly
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feeling tense or nervous
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difficulty in sleeping
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Feeling tired or lacking in energy
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Loss of interest in most things
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Feeling unhappy or depressed
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in Vaginal Maturation Index (VMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rate of sarcopenia development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Area Under the Receiver Operating Characteristic Curve (ROC-AUC) of Plasma Presepsin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic Respiratory Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ECG differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CPET results differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CA 125 elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: changes in cognitive function scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under Plasma Concentration-time Curve up to the Last Measurable Concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse to Opioid Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vessel blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: frequency and severity of self mutilation episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes